KR20230035076A - 변형된 il-2 폴리펩티드를 포함하는 폴리펩티드 및 이의 용도 - Google Patents

변형된 il-2 폴리펩티드를 포함하는 폴리펩티드 및 이의 용도 Download PDF

Info

Publication number
KR20230035076A
KR20230035076A KR1020237003798A KR20237003798A KR20230035076A KR 20230035076 A KR20230035076 A KR 20230035076A KR 1020237003798 A KR1020237003798 A KR 1020237003798A KR 20237003798 A KR20237003798 A KR 20237003798A KR 20230035076 A KR20230035076 A KR 20230035076A
Authority
KR
South Korea
Prior art keywords
polypeptide
binding domain
antigen binding
modified
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237003798A
Other languages
English (en)
Korean (ko)
Inventor
죤 씨 티머
플로리안 술츠마이어
케이트린 엠 윌리스
브라이언 벡룬트
브렌단 피 엑켈만
Original Assignee
인히브릭스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인히브릭스, 인크. filed Critical 인히브릭스, 인크.
Publication of KR20230035076A publication Critical patent/KR20230035076A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
KR1020237003798A 2020-07-02 2021-07-01 변형된 il-2 폴리펩티드를 포함하는 폴리펩티드 및 이의 용도 Pending KR20230035076A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047681P 2020-07-02 2020-07-02
US63/047,681 2020-07-02
PCT/US2021/040061 WO2022006380A2 (en) 2020-07-02 2021-07-01 Polypeptides comprising modified il-2 polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
KR20230035076A true KR20230035076A (ko) 2023-03-10

Family

ID=77127075

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237003798A Pending KR20230035076A (ko) 2020-07-02 2021-07-01 변형된 il-2 폴리펩티드를 포함하는 폴리펩티드 및 이의 용도

Country Status (12)

Country Link
US (1) US20230235005A1 (https=)
EP (1) EP4175979A2 (https=)
JP (1) JP2023532904A (https=)
KR (1) KR20230035076A (https=)
CN (1) CN116615440A (https=)
AR (1) AR122863A1 (https=)
AU (1) AU2021299552A1 (https=)
CA (1) CA3184618A1 (https=)
IL (1) IL299542A (https=)
MX (1) MX2022016532A (https=)
TW (1) TW202216745A (https=)
WO (1) WO2022006380A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4232071A4 (en) 2020-10-23 2024-08-28 Asher Biotherapeutics, Inc. FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
AU2022275666A1 (en) 2021-05-19 2023-12-07 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
US20250109203A1 (en) * 2022-01-05 2025-04-03 Inhibrx Biosciences, Inc. Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
CA3243623A1 (en) * 2022-02-11 2025-01-20 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Immunoconjugated and its use
JP2025515470A (ja) * 2022-04-27 2025-05-15 アシャ バイオセラピューティクス，インク． サイトカイン融合タンパク質とｃｄ８抗原結合分子の併用
CA3259108A1 (en) 2022-06-16 2023-12-21 Cephalon Llc Attenuated Anti-PD1-IL2 Immunoconjugates and Their Uses
TW202402784A (zh) * 2022-07-06 2024-01-16 中國商科望（上海）生物醫藥科技有限公司 Il2突變蛋白及其用途
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
EP4662237A1 (en) * 2023-02-06 2025-12-17 Merck Patent GmbH Vhh-based nkp46 binders
US20250092109A1 (en) 2023-08-30 2025-03-20 Xilio Development, Inc. Vhh masked cytokines and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PT1678314E (pt) 2003-10-22 2012-11-27 Keck Graduate Inst Métodos de síntese de polipéptidos heteromultiméricos em levedura utilizando uma estratégia de conjugação haplóide
BRPI0508470A (pt) * 2004-03-05 2007-07-31 Chiron Corp sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
WO2015164815A1 (en) * 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
KR102687530B1 (ko) * 2016-05-04 2024-07-25 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
CN116970059A (zh) * 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
JP7637415B2 (ja) * 2018-06-22 2025-02-28 キュージーン インコーポレイテッド インターロイキン－２バリアントおよびその使用方法
US11492384B2 (en) * 2018-09-17 2022-11-08 Gi Innovation, Inc. Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
KR20210113265A (ko) * 2019-01-07 2021-09-15 인히브릭스, 인크. 변형된 il-2 폴리펩타이드를 포함하는 폴리펩타이드 및 이의 용도
AU2020287373B2 (en) * 2019-06-05 2026-01-29 Asher Biotherapeutics, Inc. Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function

Also Published As

Publication number Publication date
EP4175979A2 (en) 2023-05-10
WO2022006380A3 (en) 2022-02-24
CA3184618A1 (en) 2022-01-06
US20230235005A1 (en) 2023-07-27
IL299542A (en) 2023-02-01
AU2021299552A1 (en) 2023-02-02
WO2022006380A2 (en) 2022-01-06
TW202216745A (zh) 2022-05-01
JP2023532904A (ja) 2023-08-01
MX2022016532A (es) 2023-04-12
AR122863A1 (es) 2022-10-12
CN116615440A (zh) 2023-08-18

Similar Documents

Publication Publication Date Title
JP7594161B2 (ja) 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用
US20230235005A1 (en) Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
US12012459B2 (en) OX40-binding polypeptides and uses thereof
KR20220004751A (ko) CLEC12a 결합 폴리펩타이드 및 이의 용도
JP2024526835A (ja) Ｃｄ８結合ポリペプチド及びその使用
KR20240130130A (ko) 감마 델타 t 세포 결합 폴리펩티드 및 그의 용도
WO2023004305A1 (en) Cd8-targeted modified il-2 polypeptides and uses thereof
RU2849624C2 (ru) Полипептиды, содержащие модифицированный полипептид il-2, и их применения
TWI918596B (zh) Ox40結合多肽及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902